Survodutide: How It Works, What It's Studied For & Safety
Survodutide is an investigational dual glucagon and GLP-1 receptor agonist in late-stage clinical development for chronic weight management and metabolic dysfunction-associated steatohepatitis (MASH). Clinicians consider it for chronic weight management in adults with obesity (Phase 3, SYNCHRONIZE program). Not FDA-approved; dispensed by Wells Pharmacy Network only after a clinician evaluation.
Also known as: BI 456906
How does Survodutide work?
Survodutide is a single peptide engineered to co-activate the glucagon and GLP-1 receptors. The GLP-1 component supports glucose-dependent insulin secretion, satiety, and slower gastric emptying; the glucagon component is studied for additional energy expenditure and direct hepatic effects on lipid handling.
What is Survodutide studied for?
- Chronic weight management in adults with obesity (Phase 3, SYNCHRONIZE program)
- Metabolic dysfunction-associated steatohepatitis (MASH) with liver fibrosis
- Glycemic and metabolic endpoints in type 2 diabetes (earlier-phase research)
How is Survodutide taken?
Investigational once-weekly subcutaneous injection. Not FDA-approved. Not commercially available outside of clinical trials and clinician-directed research contexts.
Is Survodutide FDA-approved? Is it safe?
Not FDA-approved for the prevention, treatment, or cure of any condition. Used inside research-informed, clinician-directed protocols only. Reported effects in trials are dominated by GI events (nausea, vomiting, diarrhea), most pronounced during dose escalation. Long-term safety in real-world populations has not yet been established. Compounded prescription-only preparations are dispensed by Wells Pharmacy Network. Eligibility is decided by a licensed clinician based on intake and labs, not by checkout. Compounded products on this site are not FDA-approved and are not generic equivalents of any branded medication.
In the Regen Therapy catalog
This compound does not currently appear in an active Regen Therapy protocol. Browse the full catalog for adjacent options.
What does the research say about Survodutide?
Phase 2 obesity and MASH trials reported substantial weight loss and a high rate of histological MASH resolution; the Phase 3 SYNCHRONIZE obesity program is ongoing.
Citations & further reading
Considering Survodutide as part of a protocol?
Browse Regen Therapy's catalog or start a clinician evaluation. Every prescription is reviewed by a licensed clinician and dispensed by Wells Pharmacy Network.
Browse the catalog →